Plant-Based Expression Systems Market is projected to grow at an annualized rate of about 12% during the period 2023-2035

smith4u 11 months ago 0 1

Given the growing clinical pipeline of biologics and advantages offered by plant-derived therapeutics, such as high scalability and eukaryotic modification of proteins, plant-based expression systems have emerged as an optimal drug development platform

Roots Analysis has announced the addition of “Plant-based Biologics and Expression Systems Market, 2022-2035” report to its list of offerings.

Plants produce high-value recombinant proteins that can be used for the preparation of pharmaceutical therapeutics, as well as non-pharmaceutical products; these proteins find applications in the development of antibodies, vaccine antigens, enzymes, growth factors, research or diagnostic reagents and cosmetic ingredients. Plant-host engineering serves as a method for the production of proteins with distinct and uniform post-translational modifications (PTMs), creating opportunities for the development of biologics having relatively increased efficacy, as compared to their mammalian cell counterparts.   

Key Market Insights

35+ players are currently engaged in offering plant-based expression systems

Close to 30% of the plant-based therapies are being developed by using benth as a protein expression host system. Other prominent plants used for the development of biologic drug candidates include tobacco, rice, wheat germ and tomato.

Over 40% of the plant-based expression system providers are based in North America

Within North America, the developer landscape is further dominated by players that are based in the US, representing around 30% of the total number of stakeholders located across the globe. Further, majority of companies (>65%) engaged in this market are small players (2-50 employees).

Get Detailed Report:

More than 45 plant-based biologics have been / are being developed for the treatment of a range of clinical conditions

Over 45% of the aforementioned therapeutic candidates are under clinical evaluation, primarily being investigated in phase II studies. Examples of approved plant-based therapies include Elelyso® (developed by Protalix Biotherapeutics) and PALFORZIA® (developed by Aimmune Therapeutics).

Over 50% plant-based therapies have been / are being developed against infectious disorders

Currently, majority of such therapies (more than 35%) are being developed against the COVID-19 infection. It is also worth noting that close to 30% of the therapies have been / are being developed as vaccines.

Partnership activity in this field has increased at a CAGR of 16%, between 2018 and 2020

Interestingly, 35% of the reported deals were instances of R&D agreements, followed by licensing agreements (30%). Further, majority of the instances captured in the report were inked by players based in North America (over 50%).

>60% publications for plant-based biologics and expression systems are research articles

Close to 135 publications have received supporting grants from various organizations. Furthermore, we have conducted a proprietary timeline analysis to calculate the average number of days for a research article to move through the different steps of the process, from receiving acceptance of the authorizing organization to being published.

North America is anticipated to capture around 40% share of the global expression systems market in 2035

Around 55% of the market revenues are further expected to be generated through transient plant-based expression systems in 2035. Further, plant-based therapies developed as monoclonal antibodies are expected to occupy a larger share (25%) of the market, followed by vaccines (24%) and biosimilars (20%).

Plant-based therapies targeting infectious disorders are anticipated to capture around 35% of the global market share in 2035

  Over 20% of the market revenues are expected to be generated from plant-based therapies being developed for the treatment of liver disorders, in 2035. This is followed by therapies being developed against respiratory disorders (~15%).

Request for Customization @

Key Questions Answered

  • Who are the key players engaged in providing plant-based expression systems?
  • What are the key plant sources used by drug developers to manufacture plant-based biologics?
  • Which are the key therapeutic areas for which plant-based biologics are being developed?
  • What are the different proprietary technologies offered / developed by plant-based expression system providers?
  • Which type of partnership models are most commonly adopted by stakeholders engaged in this domain?
  • What is the relative competitiveness of different plant-based expression system providers?
  • What is the evolving trend related to the focus of publications focused on plant-based biologics?
  • How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the plant-based expression systems and biologics market has been analyzed across the following segments:

Type of Product

  • Biosimilars
  • Cell Therapies
  • Gene Therapies
  • Monoclonal Antibodies
  • Vaccines
  • Others

Type of Plant

  • Algae
  • Barley
  • Benth
  • Duckweed
  • Lettuce
  • Maize
  • Moss
  • Rice
  • Tomato
  • Tobacco
  • Wheat Germ

Type of Expression System

  • Stable Expression System
  • Transient Expression System

Type of Target Disease Indication

  • Cirrhotic Ascites
  • COVID-19
  • Cystic Fibrosis
  • Ebola Virus Infection
  • Fabry Disease
  • Gaucher Disease
  • Liver Cirrhosis
  • Influenza
  • Peanut Allergy

Therapeutic Area

  • Genetic Disorders
  • Infectious Disorders
  • Liver Disorders
  • Respiratory Disorders
  • Others

Drug Candidate

  • Elelyso
  • OsrHSA
  • PRX-110
  • PRX-102
  • Unnamed_1
  • Unnamed_2
  • ZMapp

Geographical Region

  • North America
  • Europe
  • Asia
  • Middle East and North Africa
  • Latin America
  • Rest of the World

The research includes profiles of key players (listed below); each profile features a brief overview of company, details related to its technology portfolio, recent developments (including collaborations and expansions) and an informed future outlook.

  • medicago
  • Leaf Expression Systems
  • eleva
  • iBio
  • PlantForm
  • G+Flas lifesciences
  • Kentucky Bioprocessing
  • Angany

Request for Sample:


Read Our Latest Blogs:


Visit for More Insights:

Read Our Latest Press Release:

Latest Blogs On Healthcare Industry:


Our Service Portfolio: Pipeline Tracking | Publication Analysis | Investment Analysis | Market Assessment | Competitive Profiling | Commercial Strategy and Business Development


About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Written By

Leave a Reply

Leave a Reply

Your email address will not be published. Required fields are marked *